U.S. Pancreatic Cancer Treatment Market Size, Share & Trends Analysis Report By Type (Exocrine, Endocrine), By Treatment (Chemotherapy, Radiation Therapy, Others), By Distribution Channel,- Industry Analysis, Size, Share, Growth, Trends, and Forecast 2025-2034

U.S. Pancreatic Cancer Treatment Market Size and Research

The U.S. pancreatic cancer treatment market size was exhibited at USD 1.15 billion in 2024 and is projected to hit around USD 3.58 billion by 2034, growing at a CAGR of 12.03% during the forecast period 2025 to 2034.

U.S. Pancreatic Cancer Treatment Market Key Takeaways:

• The exocrine segment dominated the U.S. pancreatic cancer treatment market, accounting for the largest revenue share of 88.39% in 2024.
• The endocrine segment is anticipated to witness the fastest CAGR over the forecast period.
• The chemotherapy segment dominated the U.S. pancreatic cancer treatment market in 2024 with a share of 44.0%.
• The radiation therapy segment is projected to grow significantly over the forecast period.
• The hospital pharmacies segment held the largest market share of 46.01% in 2024.
• The retail pharmacies segment is the second-largest distribution channel and is expected to witness steady growth over the forecast period.

Report Scope of U.S. Pancreatic Cancer Treatment Market

The growth of the market is primarily driven by the rising incidence of pancreatic cancer, advancements in treatment modalities, and increasing awareness about early detection and treatment options. According to the American Cancer Society, in 2023, approximately 64,050 new cases of pancreatic cancer were reported in the U.S., with an estimated 50,550 deaths attributed to the disease. The grim prognosis and aggressive nature of pancreatic cancer are spurring demand for innovative treatment options, contributing to the market's growth.

Technological advancements and the development of novel therapeutics, including immunotherapy and targeted treatments, are significantly impacting the market. For instance, the adoption of nanotechnology-based drug delivery systems has improved treatment efficacy and reduced side effects. Furthermore, ongoing clinical trials for combination therapies, involving chemotherapy, radiation, and immunotherapy, are showing promising results, driving the demand for advanced pancreatic cancer treatment methods in the U.S.

The increasing incidence of pancreatic cancer in the U.S. is a major factor propelling market growth. Risk factors such as smoking, obesity, diabetes, and genetic predisposition are contributing to the rising cases. According to a study published by the National Cancer Institute in 2023, pancreatic cancer accounts for about 3% of all cancers in the U.S. and about 7% of all cancer deaths.

Additionally, the growing geriatric population is a significant driver, as the risk of developing pancreatic cancer increases with age. The U.S. Census Bureau projects that by 2030, nearly 20% of the U.S. population will be aged 65 and older, further fueling the demand for effective pancreatic cancer treatments. Government initiatives such as funding for cancer research, and partnerships between private and public sectors, are playing a critical role in market growth. For instance, the National Cancer Institute’s Pancreatic Cancer Detection Consortium (PCDC) supports research focused on early detection and treatment.

Innovations in treatment modalities are transforming the pancreatic cancer treatment landscape. Targeted therapies and immunotherapies, such as immune checkpoint inhibitors and CAR-T cell therapies, are gaining traction due to their ability to enhance survival rates with fewer side effects compared to conventional chemotherapy.

Radiation therapy has also seen advancements, with technologies like stereotactic body radiotherapy (SBRT) providing precise targeting of cancer cells while sparing healthy tissues. Additionally, liquid biopsies for early pancreatic cancer detection and monitoring have emerged as a promising diagnostic tool, enabling personalized treatment strategies. In June 2023, a major breakthrough was achieved when a leading biotech company announced FDA approval for its novel KRAS inhibitor, which has shown effectiveness in treating pancreatic tumors harboring specific genetic mutations.

U.S. Pancreatic Cancer Treatment Market By Type Insights

The exocrine segment dominated the U.S. pancreatic cancer treatment market, accounting for the largest revenue share of 88.39% in 2024. Exocrine tumors, particularly pancreatic adenocarcinomas, are the most common type of pancreatic cancers, comprising over 90% of all cases. The prevalence of exocrine pancreatic cancers is driving the demand for innovative therapies, including chemotherapy and targeted treatment options. The availability of advanced diagnostic techniques, coupled with increasing awareness about the disease, further propels growth in this segment.

The endocrine segment is anticipated to witness the fastest CAGR over the forecast period. Endocrine tumors, also known as pancreatic neuroendocrine tumors (pNETs), are less common but show unique treatment challenges and opportunities. Growing R&D efforts to develop therapies specifically targeting endocrine tumors, alongside advancements in precision medicine, are expected to contribute significantly to the growth of this segment. Increasing adoption of diagnostic imaging techniques, such as functional imaging, is also bolstering growth.

U.S. Pancreatic Cancer Treatment Market By Treatment Insights

The chemotherapy segment dominated the U.S. pancreatic cancer treatment market in 2024 with a share of 44.0%, owing to its widespread use as the first-line treatment for both exocrine and endocrine pancreatic cancers. Chemotherapy regimens, such as FOLFIRINOX and gemcitabine-based therapies, are commonly prescribed due to their effectiveness in managing advanced cases. The high prevalence of pancreatic cancer and the lack of targeted therapies for many patients contribute to chemotherapy’s dominance in the market.

The radiation therapy segment is projected to grow significantly over the forecast period, driven by advancements in precision radiation techniques such as stereotactic body radiotherapy (SBRT). These technologies offer improved targeting of cancer cells while minimizing damage to surrounding healthy tissues. Radiation therapy is increasingly being used in combination with chemotherapy and surgical interventions to improve survival rates and patient outcomes.

U.S. Pancreatic Cancer Treatment Market By Distribution Channel Insights

The hospital pharmacies segment held the largest market share of 46.01% in 2024. The dominance of this segment can be attributed to the high volume of inpatient and outpatient visits for pancreatic cancer diagnosis and treatment in hospitals. Hospitals are typically equipped with the infrastructure and skilled personnel required to administer complex therapies such as chemotherapy and radiation therapy. Additionally, the presence of specialized oncology departments in hospitals drives demand in this segment.

The retail pharmacies segment is the second-largest distribution channel and is expected to witness steady growth over the forecast period. Retail pharmacies play a vital role in providing oral chemotherapy drugs and supportive care medications, such as anti-nausea drugs and pain management therapies, to outpatients. Increasing accessibility and convenience for patients undergoing long-term treatment are key factors contributing to the growth of this segment.

Some of the prominent players in the U.S. pancreatic cancer treatment market include:

• Accuray Incorporated
• AstraZeneca
• Novartis AG
• Pfizer Inc
• Genentech, Inc (Roche Holding AG)
• Bristol-Myers Squibb Company
• Ipsen Pharma
• Eli Lilly and Company
• Elekta AB
• Siemens Healthineers AG (Varian Medical Systems, Inc., part of the company)

U.S. Pancreatic Cancer Treatment Market Recent Developments

• In August 2024, the U.S. FDA had granted orphan drug designation to Exelixis, Inc.’s cabozantinib for treating pancreatic neuroendocrine tumors (pNET) and has set a Prescription Drug User Fee Act (PDUFA) target action date of April 3, 2025.
  
  
• In February 2024, the U.S. FDA approved Ipsen’s irinotecan liposome (Onivyde) in addition to other drugs (oxaliplatin, fluorouracil, and leucovorin) for the first-line treatment of metastatic pancreatic adenocarcinoma.
  
  
• In August 2024, myTomorrows, a global health technology company, partnered with Pancreatic Cancer Europe to support patients and caregivers in accessing and navigating clinical trials and find relevant treatment options.

Segments Covered in the Report

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2034. For this study, Nova one advisor, Inc. has segmented the U.S. pancreatic cancer treatment market

By Type

• Exocrine
• Endocrine

By Treatment

• Chemotherapy
• Radiation Therapy
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Others